It is my great pleasure to invite you to The European Congress on Controversies in Lymphoma (Lymphoma2020), which will now take place on 14-15 September 2020 in Vienna, Austria.
The past few years have witnessed significant improvements in our understanding of lymphoproliferative malignancies and in our capabilities to treat patients diagnosed with these diseases. The introduction of new agents, including small molecules, non-conjugated and conjugated antibodies, and immunomodulation technologies (particularly chimeric antigen receptor T cells) has considerably changed the landscape of lymphoproliferative malignancies, with most patients achieving at least a durable response and even cure.
Prof. Irit Avivi, M.D.
BEST ABSTRACT AWARD
We look forward to hearing from you.